Integra LifeSciences
IART
238 hedge funds and large institutions have $2.07B invested in Integra LifeSciences in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 100 increasing their positions, 72 reducing their positions, and 77 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 72
5.59% more ownership
Funds ownership: 84.44% → 90.03% (+5.6%)
12% less capital invested
Capital invested by funds: $2.34B → $2.07B (-$275M)
15% less funds holding
Funds holding: 281 → 238 (-43)
53% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 77
81% less call options, than puts
Call options by funds: $312K | Put options by funds: $1.68M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$137M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$48.2M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$41.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$24.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$104M |
| 2 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$95.3M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$19.4M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$18.2M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$15.2M |
IART Hedge Fund Activity: Q2 2024 in Review
238 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2024, worth a combined $2.07B — down 12% from $2.34B a quarter earlier.
Sellers outnumbered buyers: 77 funds closed out of IART and 36 opened new positions — a net loss of 41 holders — while 72 trimmed existing stakes and 100 added.
The largest buyer was BlackRock, adding an estimated $137M. The largest seller was Capital Research Global Investors, cutting an estimated $104M.
- 238 institutional investors held Integra LifeSciences (IART) as of Q2 2024, down from 281 in Q1 2024.
- Funds reported $2.07B of Integra LifeSciences stock for Q2 2024, down 12% quarter-over-quarter.
- 36 funds opened new Integra LifeSciences positions in Q2 2024 and 77 closed out, a net change of -41 holders.
- The largest Integra LifeSciences buyer in Q2 2024 was BlackRock, an estimated $137M added.
- The largest Integra LifeSciences seller in Q2 2024 was Capital Research Global Investors, an estimated $104M sold.
Based on aggregated 13F filings for Q2 2024.